None
Conditions
Interventions
Mannatide group:Participants were instructed not to change their dietary habits or take probiotics, antibiotics, or any other medication during the study period. Volunteers take 30mg of alpha mannan p
Placebo control group:The total daily dose was 30 mg (5 mg per tablet), administered three times daily, with 10 mg each time, and an interval of approximately 6 hours between each administration, for
Sponsors
The First People's Hospital of Jintang County
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: (1) Men or women aged 18-45 who are healthy (with intact physiological and psychological functions, no defects or diseases) (2) Normal liver function and normal blood lipids (3) The subjects voluntarily participate and sign an informed consent form.
Exclusion criteria
Exclusion criteria: (1) History of colorectal disease or family history of colorectal related diseases; (2) History of liver disease; (3) Oral antibiotics and probiotics were administered four weeks prior to the study; (4) Alcoholism, drug addiction, or drug use; (5) Pregnancy or breastfeeding; (6) Within the first four weeks of the study, taking traditional Chinese medicine, polysaccharide drugs, and prebiotics such as heparin, hyaluronic acid, and inulin; (7) Serious organic diseases such as cancer, coronary heart disease, etc; (8) Patients with rheumatic heart disease, bronchial asthma, and tracheitis (9) Infectious diseases such as hepatitis B and tuberculosis; (10) Individuals who have previously experienced adverse reactions while taking mannan peptide; (11) Researchers believe that the research subjects are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in gut microbiota; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fecal metabolomics; | — |
Countries
China
Contacts
Public ContactKaijun Cui
The First People's Hospital of Jintang County
Outcome results
None listed